The message that Ainnova's CEO, Vinicio Vargas, continues to convey to audiences around the world is that this accessible, fast, and scalable solution is designed to support early intervention and ...

Detailed price information for Avant Technologies Inc (AVAI) from The Globe and Mail including charting and trades.

There’s room on the market for new TAVI valves as long as they can compete with the best in practice, a researcher says.

Real-world low-risk transcatheter aortic valve replacement (TAVR) outcomes in the United States have not been assessed comprehensively versus pivotal trials, which is a key component of measuring the ...

Hyderabad: Olive Hospital has achieved a major breakthrough in the field of Interventional Cardiology by successfully completing its first-ever Transcatheter Aortic Valve Replacement (TAVR) procedure.

The randomized, multicenter, international study compared the safety and efficacy of the Evolut TAVR system with surgery in patients with a low — less than 3% — 30-day mortality risk.

Researchers found that at five years, patients with severe aortic stenosis who were treated with either TAVR or surgery had comparable rates of all-cause mortality or disabling stroke. People who have ...

Although the study found Evolut had a slight edge over surgery, the difference was not statistically significant, an outcome similar to Edwards Lifesciences’ five-year TAVR data in 2023 that ...

Data shows, versus surgery, the Evolut transcatheter aortic valve replacement (TAVR) system delivers a numerically lower rate of all-cause mortality or disabling stroke at five years, strong valve ...

Medtronic has reported late-breaking data from the randomised Evolut Low Risk Trial’s five-year outcomes of the Evolut transcatheter aortic valve replacement (TAVR) system in low-risk aortic stenosis ...

The Evolut FX TAVR [Image courtesy of Medtronic] Chicago was the site for the latest edition of the American College of Cardiology (ACC) Scientific Sessions. There, a number of the biggest names ...